Syracuse Biopharma

Syracuse Biopharma, established by Eureka, is dedicated to the development and commercialization of Eureka’s proprietary clinical programs based on TCR-mimic and antibody-TCR ARTEMIS® technology platforms in China and ASEAN countries. Syracuse's clinical research programs include Eureka’s ARTEMIS® clinical program targeting alpha-fetoprotein (AFP) for the treatment of hepatocellular carcinoma (HCC), the most common type of liver cancer. This program is currently in Phase I/II clinical trials in the United States.